Display options
Cite
Jones PW, Gelhorn H, Karlsson N, et al. Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients. Chronic Obstr Pulm Dis. 2017;4(2):132-140doi: 10.15326/jcopdf.4.2.2017.0129.
Jones, P. W., Gelhorn, H., Karlsson, N., Menjoge, S., Müllerova, H., Rennard, S. I., Tal-Singer, R., Wilson, H., Merrill, D., & Tabberer, M. (2017). Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients. Chronic obstructive pulmonary diseases (Miami, Fla.), 4(2), 132-140. https://doi.org/10.15326/jcopdf.4.2.2017.0129
Jones, Paul W, et al. "Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 4,2 (2017): 132-140. doi: https://doi.org/10.15326/jcopdf.4.2.2017.0129
Jones PW, Gelhorn H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Wilson H, Merrill D, Tabberer M. Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients. Chronic Obstr Pulm Dis. 2017 Mar 21;4(2):132-140. doi: 10.15326/jcopdf.4.2.2017.0129. PMID: 28848922; PMCID: PMC5559112.
Copy Download .nbib Format: NLM
Share it on

Chronic Obstr Pulm Dis. 2017 Mar 21;4(2):132-140. doi: 10.15326/jcopdf.4.2.2017.0129.

Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Paul W Jones, Heather Gelhorn, Niklas Karlsson, Shailendra Menjoge, Hana Müllerova, Stephen I Rennard, Ruth Tal-Singer, Hilary Wilson, Debora Merrill, Maggie Tabberer

Affiliations

  1. Institute of Infection and Immunity, St George's University of London, United Kingdom.
  2. Research and Development, GlaxoSmithKline, Uxbridge, United Kingdom.
  3. Evidera, Bethesda, Maryland.
  4. Research and Development, AstraZeneca, Gothenburg, Sweden.
  5. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.
  6. Division of Pulmonary, Critical Care, Sleep and Allergy, Nebraska Medical Center, Omaha.
  7. Research and Development, AstraZeneca, Cambridge, United Kingdom.
  8. Research and Development, GlaxoSmithKline, King of Prussia, Pennsylvania.
  9. COPD Foundation, Washington, D.C.

PMID: 28848922 PMCID: PMC5559112 DOI: 10.15326/jcopdf.4.2.2017.0129

[No abstract available.]

Keywords: FEV1; CBQC; COPD Biomarkers Qualification Consortium; SGRQ; St George’s Respiratory Questionnaire; forced expiratory volume in 1 second; mMRC; modified Medical Research Council dyspnea scale; predictors

Conflict of interest statement

PWJ, NK, SM, HM, SIR, RTS and MT are employees and shareholders of the pharmaceutical companies who funded this analysis. HG and HW participated in this project as employees of Evidera, a company whic

References

  1. Eur Respir J. 2004 May;23(5):698-702 - PubMed
  2. N Engl J Med. 2007 Feb 22;356(8):775-89 - PubMed
  3. N Engl J Med. 2008 Oct 9;359(15):1543-54 - PubMed
  4. COPD. 2013 Jun;10(3):367-77 - PubMed
  5. Chronic Obstr Pulm Dis. 2017 Mar 13;4(2):112-123 - PubMed
  6. Chronic Obstr Pulm Dis. 2017 Apr 1;4(2):150-158 - PubMed

Publication Types